On December 13, 2024, Charles River Laboratories amended its credit agreement, reducing commitments from $3 billion to $2 billion and extending maturity to 2029. The agreement includes Charles River and its subsidiary as borrowers, with financing backed by substantial assets and stock pledges. The deal sets strict financial tests and limits on further debt and business activities.